We are live on ! Find out more
CEROW

CERo Therapeutics Warrants
CEROW

Delisted

CEROW was delisted on the 30th of October, 2025.

Back to rankings

30 hedge funds and large institutions have $28K invested in CERo Therapeutics Warrants in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

18.51% more ownership

Funds ownership: 0% → 18.51% (+19%)

12% less funds holding

Funds holding: 34 → 30 (-4)

75% less capital invested

Capital invested by funds: $110K → $28K (-$82.3K)

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

Holders
30
Holders Change
-4
Holders Change %
-11.76%
% of All Funds
0.43%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
3
Reduced
1
Closed
4
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
-$1K

Top Buyers

Rank Fund Capital Flow
1
BOCH
Blue Owl Capital Holdings
New York
+$3.73K
2
CAC
Cowen and Company
New York
+$832
3
Bank of America
Bank of America
North Carolina
+$2
4
CS
Clear Street
New York
+$2

Top Sellers

Rank Fund Capital Flow
1
SCM
Shaolin Capital Management
Florida
-$5.38K
2
KL
KIM LLC
Kansas
-$1K
3
EAM
Exos Asset Management
New York
-$74
4
PC
Periscope Capital
Ontario, Canada
-$35
Name Holding Trade Value Shares
Change 		Change in
Stake
HCM
1
Highbridge Capital Management
New York
$4.23K – – –
CAC
2
Cowen and Company
New York
$3.76K +$832 +50,100 +7%
CF
3
Cantor Fitzgerald
New York
$2.25K – – –
BOCH
4
Blue Owl Capital Holdings
New York
$2.25K +$3.73K +224,930 New
PC
5
Periscope Capital
Ontario, Canada
$2.17K -$35 -2,100 -0.5%
MI
6
MMCAP International
Cayman Islands
$1.91K – – –
SCM
7
Saba Capital Management
New York
$1.75K – – –
LA
8
Linden Advisors
New York
$1.48K – – –
CSD
9
Clear Street Derivatives
New York
$1.37K – – –
PMAM
10
Picton Mahoney Asset Management
Ontario, Canada
$1K – – –
QGA
11
Q Global Advisors
Texas
$1K – – –
Walleye Capital
12
Walleye Capital
New York
$799 – – –
CS
13
Clear Street
New York
$741 +$2 +100 +0.1%
CCM
14
Context Capital Management
California
$622 – – –
NAM
15
Nexpoint Asset Management
Texas
$555 – – –
Walleye Trading
16
Walleye Trading
New York
$449 – – –
WCMNY
17
Westchester Capital Management (New York)
New York
$383 – – –
TCM
18
Tenor Capital Management
New York
$255 – – –
YCM
19
Yakira Capital Management
Connecticut
$255 – – –
WAM
20
Wolverine Asset Management
Illinois
$223 – – –
WA
21
Whitebox Advisors
Minnesota
$128 – – –
RCM
22
Rivernorth Capital Management
Florida
$127 – – –
SSA
23
Schonfeld Strategic Advisors
New York
$76 – – –
Calamos Advisors
24
Calamos Advisors
Illinois
$64 – – –
DCM
25
Dupont Capital Management
Delaware
$64 – – –
1
2

CEROW Hedge Fund Activity: Q3 2024 in Review

30 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in CERo Therapeutics Warrants (CEROW) for Q3 2024, worth a combined $28K — down 75% from $110K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of CEROW and 1 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 3 added.

The largest buyer was Blue Owl Capital Holdings, opening a new position worth an estimated $3.73K. The largest seller was Shaolin Capital Management, exiting entirely with an estimated $5.38K sold.

  • 30 institutional investors held CERo Therapeutics Warrants (CEROW) as of Q3 2024, down from 34 in Q2 2024.
  • Funds reported $28K of CERo Therapeutics Warrants stock for Q3 2024, down 75% quarter-over-quarter.
  • 1 fund opened new CERo Therapeutics Warrants positions in Q3 2024 and 4 closed out, a net change of -3 holders.
  • The largest CERo Therapeutics Warrants buyer in Q3 2024 was Blue Owl Capital Holdings, an estimated $3.73K added.
  • The largest CERo Therapeutics Warrants seller in Q3 2024 was Shaolin Capital Management, an estimated $5.38K sold.

Based on aggregated 13F filings for Q3 2024.